---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-005674"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T16:51:59.415729+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Madrigal reports supportive MAESTRO-NASH consensus read; NASH resolution and fibrosis improvement remain significant

## Summary
- Consensus read: NASH resolution 24% (80mg) and 28% (100mg) vs 8% placebo (p<0.0001).
- Fibrosis improvement ≥1 stage: 24% (80mg) and 26% (100mg) vs 12% placebo (p<0.0001).
- Analysis used digitized biopsies when two pathologists' scores disagreed on primary endpoints.
- Results consistent with primary analysis announced Dec 19, 2022; trial continues for up to 54 months.
- Data presented at NASH-TAG Conference on Jan 6, 2023.

## SEC filing metadata
- accession: 0001193125-23-005674
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312523005674/0001193125-23-005674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312523005674/d436279d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-005674
- JSON: https://secwatch.observer/filing/0001193125-23-005674.json
- Plain text: https://secwatch.observer/filing/0001193125-23-005674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.